- Section 1 - About the Company
- Sanofi - Key Facts
- Sanofi - Key Employees
- Sanofi - Key Employee Biographies
- Sanofi - Major Products and Services
- Sanofi - History
- Sanofi - Company Statement
- Sanofi - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Affiliate
- Joint Venture
- Section 2 – Company Analysis
- Company Overview
- Sanofi - Business Description
- Business Segment: Biopharma
- Overview
- Performance
- Business Segment: Consumer Healthcare
- Overview
- Performance
- Geographical Segment: Europe
- Target Markets
- Performance
- Geographical Segment: Rest of the World
- Target Markets
- Performance
- Geographical Segment: United States
- Performance
- R&D Overview
- Sanofi - Corporate Strategy
- Sanofi - SWOT Analysis
- SWOT Analysis - Overview
- Sanofi - Strengths
- Sanofi - Weaknesses
- Sanofi - Opportunities
- Sanofi - Threats
- Sanofi - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
- Sanofi, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
- Sanofi, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Oct 29, 2024: SandboxAQ Selected by Sanofi for Quantitative AI-Driven Biomarker Identification
- Oct 25, 2024: Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments
- Oct 25, 2024: Sanofi Q3: 15.7% Sales Growth Boosted by Earlier-Than-Anticipated Vaccine Sales; 2024 Business EPS Guidance Raised Due to Strong Business Performance
- Oct 21, 2024: Sanofi’s $17bn sale of Opella to US investors advances following government deal
- Oct 04, 2024: Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
- Sep 23, 2024: Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
- Sep 20, 2024: Federal Trade Commission Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
- Sep 10, 2024: Vir Biotechnology closes Sanofi licence deal for T-cell engagers
- Aug 26, 2024: New Data Highlight Sanofi’s Scientific Innovation and Leadership in Immune-Mediated Respiratory Diseases
- Jul 25, 2024: Sanofi Q2 - Strong Performance with 10% Sales Growth; 2024 Guidance Upgraded
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Sanofi, Key Facts
- Sanofi, Key Employees
- Sanofi, Key Employee Biographies
- Sanofi, Major Products and Services
- Sanofi, History
- Sanofi, Other Locations
- Sanofi, Subsidiaries
- Sanofi, Affiliate
- Sanofi, Joint Venture
- Sanofi, Key Competitors
- Sanofi, Ratios based on current share price
- Sanofi, Annual Ratios
- Sanofi, Annual Ratios (Cont...1)
- Sanofi, Annual Ratios (Cont...2)
- Sanofi, Interim Ratios
- Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
- Sanofi, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
- Sanofi, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Sanofi, Performance Chart (2019 - 2023)
- Sanofi, Ratio Charts
- Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
- Sanofi, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook